We are live on ! Find out more
RCKTW icon

Rocket Pharmaceuticals Warrant

13 hedge funds and large institutions have $349K invested in Rocket Pharmaceuticals Warrant in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more funds holding

Funds holding: 1013 (+3)

0.23% less ownership

Funds ownership: 2.35%2.12% (-0.23%)

35% less capital invested

Capital invested by funds: $538K → $349K (-$189K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.17%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
Reduced
2
Closed
Calls
Puts
Net Calls
Net Calls Change

RCKTW Hedge Fund Activity: Q1 2025 in Review

13 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals Warrant (RCKTW) for Q1 2025, worth a combined $349K — down 35% from $538K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new RCKTW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $7.8K. The largest seller was Citadel Advisors, cutting an estimated $1.32K.

  • 13 institutional investors held Rocket Pharmaceuticals Warrant (RCKTW) as of Q1 2025, up from 10 in Q4 2024.
  • Funds reported $349K of Rocket Pharmaceuticals Warrant stock for Q1 2025, down 35% quarter-over-quarter.
  • 3 funds opened new Rocket Pharmaceuticals Warrant positions in Q1 2025 and 0 closed out, a net change of +3 holders.
  • The largest Rocket Pharmaceuticals Warrant buyer in Q1 2025 was Susquehanna International Group, an estimated $7.8K added.
  • The largest Rocket Pharmaceuticals Warrant seller in Q1 2025 was Citadel Advisors, an estimated $1.32K sold.

Based on aggregated 13F filings for Q1 2025.